Evolus, Inc. (EOLS) Stock Price & Analysis
Evolus, Inc. (EOLS) closed at USD 7.57 on Thursday, October 15, 2026, up 4.85% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.22; the Oct 15, 2026 session ranged USD 7.23–7.71 on volume of 901,455 shares. Market capitalization is $500.00M, with a 52-week range of USD 3.86–9.31 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EOLS.md
Key facts (EOLS)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 15 (range 12–20).
- Total return with dividends: 1Y +20.2% vs S&P 500 +18.1%; 5Y -1.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.07, revenue estimate $77.6M.
Analysts (EOLS)
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 15 (low 12, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-25 | HC Wainwright & Co. | Reiterated | Buy | $13 |
Total return (dividends reinvested) (EOLS)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +20.2% | -1.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +20.2% | -0.3% |
| Volatility (annualized) | 64.4% | 63.8% |
| Max drawdown | -46.5% (Nov 2025→Mar 2026) | -77.1% (Sep 2024→Mar 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 7.57 |
|---|---|
| Change | ▲ 4.85% (up) |
| Previous Close | USD 7.22 |
| Open | USD 7.26 |
| Day Range | USD 7.23 – 7.71 |
| 52-Week Range | USD 3.86 – 9.31 |
| Volume | 901,455 shares |
| Market Cap | $500.00M |
| Exchange | NGM |
Technical Analysis (EOLS)
Nexqual's technical model rates EOLS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.5 (neutral) |
| vs SMA50 | Below (USD 8.13) |
| MACD | -0.15 (negative) |
Analyst Ratings (EOLS)
Wall Street analysts rate EOLS "Buy" based on 6 analysts, with a mean price target of USD 15 (range USD 12–20), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 15 |
| High Target | USD 20 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (EOLS)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $77.58M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.02 vs est -0.04 ▲ beat |
| 2026-03-31 | USD -0.05 vs est -0.12 ▲ beat |
| 2025-12-31 | USD 0.01 vs est 0.04 ▼ miss |
| 2025-09-30 | USD -0.15 vs est -0.18 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (EOLS)
| Total Revenue | $316.49M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +21.20% |
| Gross Margin | +66.40% |
| Operating Margin | -5.17% |
| Profit Margin | -10.85% |
| Current Ratio | 1.7 |
| Total Cash | $45.17M |
| Total Debt | $164.80M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (EOLS)
Nexqual rates Evolus, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 66%, operating -5% |
| Balance Sheet | Mixed — $45M cash vs $165M debt |
| Cash Flow | Weak — Operating cash flow -$15M (TTM) |
| Efficiency | Mixed — No data |
Ownership (EOLS)
| Insider Ownership | +11.25% |
|---|---|
| Institutional Ownership | +77.77% |
| Shares Outstanding | 66.05M |
| Float | 49.77M |
| Short % of Float | +8.63% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (EOLS)
Evolus, Inc. is led by David Moatazedi (age 47), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| President, CEO & Director | David Moatazedi (age 47) |
|---|---|
| Chief Financial Officer | Tatjana Mitchell |
| Senior Vice President of Sales | Kurt Knab |
| Senior Vice President of Human Resources | Jessica Novak |
Major Backers & Investors (EOLS)
Notable institutional backers of Evolus, Inc. include Nantahala Capital Management, LLC, Braidwell LP , Frazier Life Sciences Management, L.P. , according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 8.48% |
| Braidwell LP | 4.78% |
| Frazier Life Sciences Management, L.P. | 3.98% |
| Perceptive Advisors Llc | 3.72% |
| Millennium Management | 2.71% |
| Stonepine Capital Management, LLC | 2.41% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.83% |
| Vanguard Group | 7.53% |
| State Street | 3.28% |
| Geode Capital | 2.44% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt